164 related articles for article (PubMed ID: 24833256)
21. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
[TBL] [Abstract][Full Text] [Related]
23. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.
File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ
BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925
[TBL] [Abstract][Full Text] [Related]
24. Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.
Solomkin J; Evans D; Slepavicius A; Lee P; Marsh A; Tsai L; Sutcliffe JA; Horn P
JAMA Surg; 2017 Mar; 152(3):224-232. PubMed ID: 27851857
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
Hwang JJ; Lee DH; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Sep; 21(35):10234-41. PubMed ID: 26401089
[TBL] [Abstract][Full Text] [Related]
26. Update on the cardiac safety of moxifloxacin.
Haverkamp W; Kruesmann F; Fritsch A; van Veenhuyzen D; Arvis P
Curr Drug Saf; 2012 Apr; 7(2):149-63. PubMed ID: 22873499
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Hoeffken G; Meyer HP; Winter J; Verhoef L;
Respir Med; 2001 Jul; 95(7):553-64. PubMed ID: 11453311
[TBL] [Abstract][Full Text] [Related]
28. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
Portier H; Brambilla C; Garre M; Paganin F; Poubeau P; Zuck P
Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):367-76. PubMed ID: 15944847
[TBL] [Abstract][Full Text] [Related]
29. Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial.
Rhee CK; Chang JH; Choi EG; Kim HK; Kwon YS; Kyung SY; Lee JH; Park MJ; Yoo KH; Oh YM
Int J Chron Obstruct Pulmon Dis; 2015; 10():2265-75. PubMed ID: 26543359
[TBL] [Abstract][Full Text] [Related]
30. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
31. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.
Wilson R; Allegra L; Huchon G; Izquierdo JL; Jones P; Schaberg T; Sagnier PP;
Chest; 2004 Mar; 125(3):953-64. PubMed ID: 15006954
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
33. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.
Sethi S; Jones PW; Theron MS; Miravitlles M; Rubinstein E; Wedzicha JA; Wilson R;
Respir Res; 2010 Jan; 11(1):10. PubMed ID: 20109213
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI).
Kuzman I; Bezlepko A; Kondova Topuzovska I; Rókusz L; Iudina L; Marschall HP; Petri T
BMC Pulm Med; 2014 Jun; 14():105. PubMed ID: 24975809
[TBL] [Abstract][Full Text] [Related]
35. Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies.
Gavin JR; Kubin R; Choudhri S; Kubitza D; Himmel H; Gross R; Meyer JM
Drug Saf; 2004; 27(9):671-86. PubMed ID: 15230648
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
Patel T; Pearl J; Williams J; Haverstock D; Church D
Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.
Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
World J Gastroenterol; 2015 Apr; 21(16):5032-8. PubMed ID: 25945019
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.
File TM; Goldberg L; Das A; Sweeney C; Saviski J; Gelone SP; Seltzer E; Paukner S; Wicha WW; Talbot GH; Gasink LB
Clin Infect Dis; 2019 Nov; 69(11):1856-1867. PubMed ID: 30722059
[TBL] [Abstract][Full Text] [Related]
39. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection.
Giordano P; Song J; Pertel P; Herrington J; Kowalsky S
Int J Antimicrob Agents; 2005 Nov; 26(5):357-65. PubMed ID: 16229991
[TBL] [Abstract][Full Text] [Related]
40. Moxifloxacin five-day therapy versus placebo in acute bacterial rhinosinusitis.
Hadley JA; Mösges R; Desrosiers M; Haverstock D; van Veenhuyzen D; Herman-Gnjidic Z
Laryngoscope; 2010 May; 120(5):1057-62. PubMed ID: 20422704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
